Patents Assigned to Medical Centre
-
Patent number: 10906970Abstract: The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.Type: GrantFiled: April 16, 2018Date of Patent: February 2, 2021Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Publication number: 20200392588Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: August 24, 2020Publication date: December 17, 2020Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 10485860Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.Type: GrantFiled: November 17, 2016Date of Patent: November 26, 2019Assignee: Stichting Katholieke Universiteit / Radboud University Nijmegen Medical CentreInventors: Hester Jeanette Bootsma, Pieter Jan Burghout, Peter Wilhelmus Maria Hermans, Johanna Jacoba Elisabeth Bijlsma, Oscar Paul Kuipers, Tomas Gerrit Kloosterman
-
Patent number: 10350298Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.Type: GrantFiled: July 7, 2011Date of Patent: July 16, 2019Assignees: Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre, Stichting Katholieke Universiteit, meer in het bijzonder Radboud Universiteit NijmegenInventors: Alan Edward Rowan, Carl Gustav Figdor
-
Publication number: 20180244765Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: ApplicationFiled: April 16, 2018Publication date: August 30, 2018Applicant: ERASMUS UNIVERSITY MEDICAL CENTRE ROTTERDAMInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9951390Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: GrantFiled: April 13, 2016Date of Patent: April 24, 2018Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 9896729Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.Type: GrantFiled: August 31, 2012Date of Patent: February 20, 2018Assignees: The University of Manchester, National Institute of Aging, Hospital District of Helsinki and UUSIMAA, VU University Medical Centre Armsterdam, UCL Business PLC, University College Cardiff Consultants LimitedInventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
-
Publication number: 20170073776Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: ApplicationFiled: November 30, 2016Publication date: March 16, 2017Applicants: Stichting Katholieke Universiteit, more particularly The University Medical Centre Nijmege, The Johns Hopkins UniversityInventors: Marion J.G. Bussemakers, William B. Isaacs
-
Patent number: 9540696Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: GrantFiled: September 23, 2013Date of Patent: January 10, 2017Assignees: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, The Johns Hopkins UniversityInventors: Marion J. G. Bussemakers, William B. Isaacs
-
Patent number: 9353179Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: March 15, 2013Date of Patent: May 31, 2016Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9346877Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: March 15, 2013Date of Patent: May 24, 2016Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 9320679Abstract: A moxibustion device includes a handle, a moxa stick clamping unit, a front fixing component, a front rolling ring, a front roller cover, a traditional Chinese medicine (moxa stick), a back roller cover, a back bearing, a back fixing component, a roller's inner screen and a rotary drum. The moxibustion device is of a more ergonomic design and allows for more accurate and more direct application of force and/or rolling on acupuncture points; it is applicable to the parts of body with a small bending scope such as joints of the limbs and cervical vertebra and large-area skin such as the waist and the back. It can be easily operated, and the acupuncture points and the main and collateral channels can be acutely located.Type: GrantFiled: July 18, 2012Date of Patent: April 26, 2016Assignee: Traditional Chinese Medical Centre LimitedInventor: Kin Ming Lee
-
Publication number: 20150307948Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: June 22, 2015Publication date: October 29, 2015Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Publication number: 20150252421Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.Type: ApplicationFiled: August 31, 2012Publication date: September 10, 2015Applicants: THE UNIVERSITY OF MANCHESTER, NATIONAL INSTITUTE ON AGING, HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA, VU UNIVERSITY MEDICAL CENTRE AMSTERDAM, UCL BUSINESS PLC, UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
-
Patent number: 9096907Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: GrantFiled: June 10, 2013Date of Patent: August 4, 2015Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 8921524Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: December 23, 2009Date of Patent: December 30, 2014Assignee: Erasmus University Medical CentreInventors: Franklin Geradus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Patent number: 8921522Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: GrantFiled: December 23, 2009Date of Patent: December 30, 2014Assignee: Erasmus University Medical CentreInventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Publication number: 20140017774Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicants: The Johns Hopkins University, Stichting Katholieke Universiteit, more particularly The Univ. Medical Centre NijmegenInventors: Marion J.G. Bussemakers, William B. Isaacs
-
Patent number: 8551699Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: GrantFiled: October 30, 2009Date of Patent: October 8, 2013Assignees: Stichting Katholieke Universiteit, more particularly The University of Medical Centre Nijmegen, The Johns Hopkins UniversityInventors: Marion J. G. Bussemakers, William B. Isaacs
-
Publication number: 20130261171Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: June 10, 2013Publication date: October 3, 2013Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, Alfred J. Witjes